Neuraxis, INC (NRXS) stock
NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 0/30
$4.87+0.26 (+5.64%)
Close on Nov 18, 2026Market cap $61.16MP/E –Yield –
Neuraxis r&d expenses
Research and development expenses are spending on new products and technology.
Neuraxis's R&D Expenses for the twelve months ending Jun 30, 2026 was $650.94K, up 30.8% year over year. For fiscal 2025 it was $493.61K, up 13.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $493.61K | +13.8% |
| FY2024 | Dec 31, 2024 | $433.61K | +156.1% |
| FY2023 | Dec 31, 2023 | $169.32K | -25.0% |
| FY2022 | Dec 31, 2022 | $225.61K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $274.34K | +138.2% |
| Q1 FY2026 | Mar 31, 2026 | $99.57K | -15.5% |
| Q4 FY2025 | Dec 31, 2025 | $146.18K | +5.6% |
| Q3 FY2025 | Sep 30, 2025 | $130.85K | +3.6% |
| Q2 FY2025 | Jun 30, 2025 | $115.20K | +112.1% |
| Q1 FY2025 | Mar 31, 2025 | $117.87K | +2016.1% |
| Q4 FY2024 | Dec 31, 2024 | $138.43K | +208.0% |
| Q3 FY2024 | Sep 30, 2024 | $126.25K | +15.0% |
| Q2 FY2024 | Jun 30, 2024 | $54.31K | +223.3% |
| Q1 FY2024 | Mar 31, 2024 | $5.57K | -93.2% |
| Q3 FY2023 | Sep 30, 2023 | $44.95K | -47.8% |
| Q2 FY2023 | Jun 30, 2023 | $109.79K | +703.4% |
| Q1 FY2023 | Mar 31, 2023 | $16.80K | – |
| Q4 FY2022 | Dec 31, 2022 | $81.37K | – |
| Q3 FY2022 | Sep 30, 2022 | $86.18K | – |
| Q2 FY2022 | Jun 30, 2022 | $13.67K | – |
See a number that looks wrong?